Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Hyperopia: early-phase trial registry

2 of 11 indexed Hyperopia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 2 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Hyperopia: 11 US clinical trials tracked, 2 recruiting.

Hyperopia is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is CooperVision International Limited (CVIL), running 2 of these trials.

Enrollment posture brief

Registry condition hyperopia

OPEN 2 | RECR 18% | LATE 0 | EARLY 1 | RANK #1577 | SPON 2

Nearest open-share peer: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (18% recruiting · 22 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Hyperopia (this)18%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Hyperopia

Hyperopia lists 2 open slots (18% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hyperopia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hyperopia is recruiting below its size-band peers.

    2 of 11 indexed trials (18.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Hyperopia research.

    CooperVision International Limited (CVIL) accounts for 2 of 11 trials (18.2%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Hyperopia enrolment sits around 80 participants.

    Median target enrolment is 80 among the 11 trials that report a genuine target (sentinel values excluded). 6 of those (54.5%) plan for fewer than 100 participants.

  4. Hyperopia research is mostly interventional.

    10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21

Open and recent trials

11 total, page 1 of 1

RECRUITING NA 250 participants

Comprehensive Assessment of Multiple Products (CAMP)

CooperVision International Limited (CVIL)

NCT07276347

RECRUITING NA 66 participants

A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add

CooperVision International Limited (CVIL)

NCT06869044

ACTIVE NOT RECRUITING NA 140 participants

Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism

Bausch & Lomb Incorporated

NCT05264623

COMPLETED NA 249 participants

Hyperopia Treatment Study 1 (HTS1) - Glasses vs Observation

Jaeb Center for Health Research

NCT01515475

COMPLETED NA 167 participants

Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors

Abbott Medical Optics

NCT01675479

COMPLETED 108 participants

Air Optix Night and Day Aqua (AONDA) Retrospective Study 1

Alcon Research

NCT05790928

COMPLETED NA 80 participants

A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia

Bausch & Lomb Incorporated

NCT00348205

COMPLETED NA 53 participants

Performance Evaluation of Reusable Contact Lenses When Worn For One Month By Habitual Soft Contact Lens Wearers

CooperVision

NCT06098339

COMPLETED NA 50 participants

Apioc Contact Lens Feasibility

Lentechs

NCT03688672

COMPLETED NA 44 participants

Clinical Investigation of the WaveLight® EX500 Excimer Laser

Alcon Research

NCT04805593

COMPLETED Phase 2 35 participants

Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control

University of Florida

NCT05477875

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Hyperopia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

oral codeine/acetaminophen Combination
1 trials
oral cannabinoid Drug
1 trials
Lotrafilcon A spherical contact lenses Device
1 trials
Lens B (lotrafilcon B) Device
1 trials
Lens A (fanfilcon A) Device
1 trials
Apioc Contact Lens Design Device
1 trials
Technolas 217z Zyoptix Laser Device
1 trials
LASIK correction of hyperopic refractive errors Device
1 trials

US sites by state

Facility locations filed on Hyperopia trials. A trial with sites in several states counts in each.

Florida 5 trials
Texas 3 trials
California 3 trials
Pennsylvania 2 trials
Ohio 2 trials
New York 2 trials
Missouri 2 trials
Minnesota 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hyperopia page

11 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hyperopia condition card totals 11 registered trials; most-linked intervention oral codeine/acetaminophen; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.